Determination of Paraoxonase 1 Activity and Phenotype Distribution in Cervical Disk Herniation Patients

Year 2024, , 234 - 239, 28.08.2024

Utku Adilay , Salim Katar , Kübra Çıkrıkcı , Nahit Gençer

https://doi.org/10.53424/balikesirsbd.1403834

Abstract

Determination of Paraoxonase 1 Activity and Phenotype Distribution in Cervical Disk Herniation Patients

Abstract
Objectives: Cervical disk herniation (CDH) is a common disease that usually develops as a result of intervertebral disk degeneration (IVDD) or trauma, which can cause pain or neurological deficiency by nevre root or spinal cord compression. Paraoxonase 1 (PON1) has antioxidant qualities, and its function may vary based on genetic variations and ethnic background. This study aims to compare PON1 activity and phenotype distribution in CDH patients and individuals without the condition.
Materials and Methods: This study involved 70 CDH patients and 70 individuals in good health. Spectrophotometric tests were conducted to measure the serum PON1 and arylesterase (ARE) activities. The PON1 ratio, which indicates the salt-stimulated PON/ARE level, showed a three-peak distribution. This ratio was utilized to determine the various phenotypes; QQ, QR, and RR for each participant.
Results: The PON1 activity was lower in CDH patients compared to the healthy individuals (p < 0.05). CDH patients exhibited a statistically significant QQ phenotype in comparison to the healthy participants (p < 0.05).
Conclusion: Patients with CDH exhibited significantly reduced PON1 activity, indicating that low PON1 activity and the PON1 QQ phenotype could potentially be a risk factor for the development of CDH.
Keywords: Cervical disk herniation, Paraoxonase, Phenotype, PON1

Keywords

Cervical disk herniation, Paraoxonase, Phenotype, PON1

Ethical Statement

This study received approval from the Balıkesir University Clinical Research Ethics Committee (Decision No. 2022/93, Date: 07/09/2022).

References

• Ayan, D., Senes, M., Caycı, A. B., Söylemez, S., Eren, N., Altuntas, Y., & Oztürk, F. Y. (2019). Evaluation of paraoxonase, aryylesterase and homocysteine thiolactonase activities in patients with diabetes and incipient diabetic nephropathy. Journal of Medical Biochemistry, 38, 481–488. https://doi.org/10.2478/jomb-2019-0014
• Bailey, R. W., & Badgley, C. E. (1960). Stabilization of the cervical spine by anterior fusion. Journal of Bone and Joint Surgery, 42, 565-59
• Balcı, Ö.E., Donma, O., & Ekmekçi, H. (2004). Paraokonaz. Cerrahpaşa Tıp Derg, 35, 78-82.
• Bassu, S., Mangoni, A. A., Argiolas, D., Carru, C., Pirina, P., Fois, A. G., & Zinell, A. (2022). A systematic review and meta-analysis of paraoxonase 1 activity in asthma. Clinical and Experimental Medicine, 23, 1067–1074. https://doi.org/10.1007/s10238-022-00930-0
• Boger, D. C. (1986). Traction device to improve CT imaging of lower cervical spine. AJNR, 7, 719.
• Borovkova, E. I., Antipova, N. V., Komeenko, T. V., Shakparonov, M. I., & Borovkov, I. M. (2017). Paraoxonase: The universal factor of antioxidant defense in human body. Vestn Ross Akad Med Nauk, 72(1), 5–10. https://doi.org/10.15690/vramn764
• Chen, F., Liu, H., Li, Z., Pei, Y., Wang, H., Zhang, J., Wang, J., & Zheng, Z. (2019). Paraoxonase 1 was negatively associated with intervertebral disc degeneration. Spine (PhilaPa 1976), 44(18), E1053-E1062. https://doi.org/10.1097/brs.0000000000003059
• Costa, L. G., Giordano, G., & Furlong, C. E. (2011). Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. Biochem Pharmacol, 81(3), 337-344. https://doi.org/10.1016/j.bcp.2010.11.008
• Deakin, S., Leviev, I., Gomaraschi, M., Calabresi, L., Francesshini, G., & James, R. W. (2002). Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high-affinity, saturable, desorption mechanism. Journal of Biological Chemistry, 277, 4301–4308. https://doi.org/10.1074/jbc.M107440200
• Dimozi, A., Mavrogonatou, E., & Sklirou, A. (2015). Oxidative stress inhibits the proliferation, induces premature senescence and promotes a catabolic phenotype in human nucleus pulposus intervertebral disc cells. European Cell Materials, 30, 89-102. https://doi.org/10.22203/ecm.v030a07
• Draganov, D. I., & La Du, B. N. (2004). Pharmacogenetics of paraoxonases: A brief review. Naunyn-Schmiedeberg's Archives of Pharmacology, 369, 78-88. https://doi.org/10.1007/s00210-003-0833-1
• Eckerson, H. W., Wyte, C. M., & La Du, B. N. (1983). The human serum paraoxonase/arylesterase polymorphism. American Journal of Human Genetics, 35, 1126-1138.
• Ethemoğlu, K. B., & Erkoç, Y. S. (2020). Is there any relationship between cervical disc herniation and blood inflammatory response? Cureus, 12(8), e10161. https://doi.org/10.7759/cureus.10161
• Furlong, C. E., Marsillach, J., Jarvik, G. P., & Costa, L. G. (2016). Paraoxonases-1, -2, and -3: What are their functions? Chemical Biology & Interactions, 259, 51-62. https://doi.org/10.1016%2Fj.cbi.2016.05.036
• Karabağ, H., & Sezen, H. (2016). The relation of lumbar disc herniation with increased lipid hydroperoxide, paraoxonase 1, and total oxidative status. Crescent Journal of Medical and Biological Sciences, 3(3), 86-90. https://sid.ir/paper/344940/en
• La Du, B. N., & Eckerson, H. W. (1984). The polymorphic paraoxonase/arylesterase isozymes of human serum. Federation Proceedings, 43(8), 2338-2341.
• Mackness, M., & Mackness, B. (2015). Human paraoxonase-1 (PON1): Gene structure and expression, promiscuous activities and multiple physiological roles. Gene, (1), 12–21. https://doi.org/10.1016/j.gene.2015.04.088
• Mirdamadi, H. Z., Sztanek, F., Derdak, Z., Seres, Z., Seres, I., Harangi, M., & Paragh, G. (2008). The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters. British Journal of Clinical Pharmacology, 66(3), 366-374. https://doi.org/10.1111/j.1365-2125.2008.03213.x
• Mouhamed, D., Ezzaher, A., Mechri, A., Neffati, F., Omezzine, A., Bouslama, A., Gaha, L., Douki, W., & Najjar, M. (2012). Effect of cigarette smoking on paraoxonase 1 activity according to PON1 L55M and PON1 Q192R gene polymorphisms. Environmental Health and Preventive Medicine, 17(4), 316–321. https://doi.org/10.1007%2Fs12199-011-0256-4
• Risbud, M. V., & Shapiro, I. M. (2014). Role of cytokines in intervertebral disc degeneration: Pain and disc content. Nature Reviews Rheumatology, 10(1), 44-56. https://doi.org/10.1038/nrrheum.2013.160
• Sarioglu, N., Hismiogullari, A. A., Erel, F., Demir, D., & Gencer, D. (2015). Paraoxonase 1 phenotype and paraoxonase activity. Iranian Journal of Allergy, Asthma, and Immunology, 14(1), 60-66.
• Zhao, Y., Ma, Y., Fang, Y., Liu, L., Wu, S., Fu, D., & Wang, X. (2012). Association between PON1 activity and coronary heart disease risk: A meta-analysis based on 43 studies. Molecular Genetics and Metabolism, 105, 141–148. https://doi.org/10.1016/j.ymgme.2011.09.018